EBioMedicine

Scope & Guideline

Fostering innovation through open-access discovery.

Introduction

Welcome to your portal for understanding EBioMedicine, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN2352-3964
PublisherELSEVIER
Support Open AccessYes
CountryNetherlands
TypeJournal
Convergefrom 2014 to 2024
AbbreviationEBIOMEDICINE / EBioMedicine
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressRADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS

Aims and Scopes

EBioMedicine aims to advance the field of biomedical research by publishing high-quality studies that contribute to our understanding of disease mechanisms, therapeutic strategies, and preventive measures. The journal emphasizes interdisciplinary research that integrates clinical and translational science, fostering collaboration among researchers, clinicians, and policy makers.
  1. Clinical and Translational Research:
    The journal focuses on studies that bridge the gap between laboratory research and clinical application, highlighting research that leads to the development of new diagnostic tools, treatment strategies, and preventive measures for diseases.
  2. Biomarker Discovery and Validation:
    A significant emphasis is placed on the identification and validation of biomarkers that could aid in disease diagnosis, prognosis, and treatment response, particularly in cancer, infectious diseases, and chronic conditions.
  3. Immunology and Infectious Diseases:
    Research on the immune response to infections, including the development of vaccines and therapeutic interventions, is a core area of focus, especially in the context of emerging infectious diseases like COVID-19.
  4. Genomics and Personalized Medicine:
    The journal publishes studies leveraging genomic data to tailor medical treatments to individual patient profiles, advancing the field of precision medicine across various diseases.
  5. Microbiome Research:
    The role of the microbiome in health and disease, including its impact on metabolic disorders, immune response, and treatment outcomes, is a growing area of interest in the journal.
  6. Novel Therapeutics and Drug Development:
    Studies investigating new therapeutic approaches, including drug repurposing, nanomedicine, and gene therapies, are highlighted, emphasizing innovative strategies to combat diseases.
Recent trends in EBioMedicine reflect a shift toward innovative and multidisciplinary research themes, aligning with current global health challenges and advancements in biomedical science.
  1. Artificial Intelligence and Machine Learning:
    The integration of AI and machine learning in research methodologies is increasingly prominent, with studies focusing on predictive modeling, diagnostic algorithms, and personalized treatment strategies.
  2. Long COVID and Post-Acute Sequelae:
    Research addressing the long-term effects of COVID-19, including post-acute sequelae, is rapidly expanding, reflecting the ongoing impact of the pandemic on public health.
  3. Metabolomics and Lipidomics:
    There is a growing focus on metabolomic and lipidomic profiling to understand disease mechanisms and identify biomarkers, particularly in metabolic disorders and cancer.
  4. Immunotherapy and Immune Profiling:
    Studies exploring immunotherapy, including novel approaches and immune profiling for various cancers, are gaining traction, driven by advances in understanding the immune system.
  5. Microbiome-Health Interactions:
    Research on the interactions between the microbiome and various health conditions, including metabolic and autoimmune diseases, is emerging as a significant area of interest.
  6. Genetic and Epigenetic Research:
    The exploration of genetic and epigenetic factors influencing disease susceptibility and treatment response is on the rise, particularly in chronic diseases and cancers.

Declining or Waning

While EBioMedicine has consistently published impactful research, certain themes are showing signs of declining prominence in recent publications. This shift may reflect changes in research focus or evolving scientific priorities.
  1. Traditional Pharmacology:
    Research focusing solely on traditional pharmacological approaches without considering personalized or genomic strategies is becoming less common, as the field moves towards more tailored therapeutic interventions.
  2. Single-Disease Focus:
    There is a noticeable decline in studies that concentrate exclusively on single diseases without considering the broader implications or comorbidities, as interdisciplinary approaches gain traction.
  3. Basic Science Without Clinical Relevance:
    Basic research studies that do not translate into clinical applications or relevance are being overshadowed by studies emphasizing translational impact, as the demand for clinically applicable findings increases.
  4. Static Models of Disease:
    Research using static models that do not account for dynamic biological processes or the complexity of disease interactions is less favored, with a shift towards more comprehensive and integrated modeling approaches.
  5. Conventional Imaging Techniques:
    There is a waning interest in conventional imaging techniques as advanced technologies, including AI-based methods and multimodal imaging, become more prevalent in research design.

Similar Journals

BIOMARKERS

Pioneering Research in Biochemistry and Toxicology
Publisher: TAYLOR & FRANCIS LTDISSN: 1354-750XFrequency: 8 issues/year

BIOMARKERS is a distinguished journal published by Taylor & Francis Ltd, focusing on the critical intersection of biochemistry, clinical biochemistry, and health-related toxicology. With a robust history of publication since 1996 and ongoing contributions through to 2024, the journal serves as a vital platform for researchers, professionals, and students keen on exploring innovative biomarker research that spans various domains within the life sciences. The journal is currently ranked in the Q3 quartile in key areas such as Biochemistry and Health, demonstrating its reputation in the scientific community. Although it operates under a subscription model, BIOMARKERS remains an essential resource for advancing knowledge on biomarkers in health and disease, reflecting the latest advancements and methodologies within the rapidly evolving landscape of biomedical research. Researchers looking to publish in this influential journal can expect a rigorous peer-review process aimed at ensuring the dissemination of high-quality scientific inquiry.

Biomarkers in Medicine

Unlocking the Potential of Biomarkers in Healthcare
Publisher: FUTURE MEDICINE LTDISSN: 1752-0363Frequency: 24 issues/year

Biomarkers in Medicine is a prominent academic journal dedicated to advancing the field of medical biochemistry and drug discovery. Published by Future Medicine Ltd in the United Kingdom, this journal aims to provide a platform for researchers, clinicians, and biotechnology professionals to share their findings on the critical role of biomarkers in diagnosis, treatment, and prognosis of various diseases. With a focus on high-quality, peer-reviewed research, Biomarkers in Medicine supports the dissemination of innovative approaches and therapeutic developments across its converged publication years from 2008 to 2024. Rated in the Q3 category for biochemistry (medical), clinical biochemistry, and drug discovery, it occupies a significant place in its field, attracting contributions that push the boundaries of knowledge and application. Although it does not offer open access, the journal remains committed to excellence and rigor in the representation of ground-breaking studies, making it an essential resource for scholars and professionals eager to stay at the forefront of biomarker research.

CANCER GENE THERAPY

Exploring Breakthroughs in Cancer Gene Innovations
Publisher: SPRINGERNATUREISSN: 0929-1903Frequency: 12 issues/year

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

Yakut Medical Journal

Elevating the standards of health sciences through rigorous peer review.
Publisher: RUSSIAN ACAD SCIENCES SIBERIAN BRANCHISSN: 1813-1905Frequency: 4 issues/year

Yakut Medical Journal is a peer-reviewed academic journal published by the Russian Academy of Sciences, Siberian Branch, dedicated to advancing knowledge in the field of medicine and health sciences. With its ISSN number 1813-1905 and E-ISSN 2312-1017, this journal serves as a vital platform for researchers and professionals in Siberia and beyond, fostering the dissemination of original research, case studies, and reviews that address the unique medical challenges and innovations in this region. Although it operates under a traditional publishing model, Yakut Medical Journal is committed to upholding high academic standards, ensuring all submissions are rigorously peer-reviewed to maintain the integrity of published work. The journal aims to bridge gaps in medical research and practice through its scope, which encompasses a wide range of medical disciplines, thereby engaging a diverse audience including researchers, medical educators, and practitioners looking to stay at the forefront of medical advancements. For those keen on contributing to the field or seeking current insights, Yakut Medical Journal represents a significant addition to the body of scholarly resources available in medical literature.

EUROPEAN JOURNAL OF IMMUNOLOGY

Unlocking the Secrets of the Immune System
Publisher: WILEYISSN: 0014-2980Frequency: 12 issues/year

Welcome to the European Journal of Immunology, a premier peer-reviewed journal dedicated to advancing the field of immunology and allergy research. Established in 1971 and published by Wiley, this esteemed journal has been consistently ranked in the top quartile (Q1) across its categories, highlighting its significant impact within the scientific community. With an impressive Scopus ranking, the journal occupies the 64th position in Immunology and Allergy and the 74th in the broader sector of Immunology and Microbiology, demonstrating its vital role in driving innovation and knowledge in immunological studies. The European Journal of Immunology publishes high-quality original research, comprehensive reviews, and insightful commentary, making it an indispensable resource for researchers, healthcare professionals, and students dedicated to understanding the complexities of the immune system. Although not an open-access journal, it offers various subscription options to ensure that institutions and individuals can access pivotal research that shapes the future of immunology.

CURRENT OPINION IN IMMUNOLOGY

Leading the Charge in Immunology Insights
Publisher: CURRENT BIOLOGY LTDISSN: 0952-7915Frequency: 6 issues/year

CURRENT OPINION IN IMMUNOLOGY is a prestigious journal dedicated to the dynamic field of immunology, published by CURRENT BIOLOGY LTD in the United Kingdom. With an ISSN of 0952-7915 and an E-ISSN of 1879-0372, this journal has been a cornerstone of scholarly communication since its inception in 1988 and continues to disseminate cutting-edge research and reviews aimed at advancing our understanding of immune responses. Holding a remarkable Q1 ranking in both Immunology and Allergy categories for 2023, it ranks impressively within the top percentiles in its field, securing 27th233 in Immunology and Allergy and 31st out of 236 in Immunology and Microbiology. Emphasizing high-impact research, the journal provides researchers, professionals, and students with valuable insights into emerging trends and critical developments. As a vital resource in immunological research, it serves as a platform for disseminating innovative findings, fostering collaboration, and enhancing scholarly exchange in a rapidly evolving scientific landscape.

TRENDS IN IMMUNOLOGY

Shaping the Future of Immunology Through Comprehensive Reviews
Publisher: CELL PRESSISSN: 1471-4906Frequency: 12 issues/year

TRENDS IN IMMUNOLOGY, published by CELL PRESS, stands as a premier source of insights and developments within the field of immunology. With an ISSN of 1471-4906 and E-ISSN of 1471-4981, this journal has established a strong reputation, evidenced by its prestigious status in Q1 quartiles for both Immunology and Allergy in 2023. It is ranked #13 out of 233 in the Scopus category of Medicine – Immunology and Allergy, and #16 out of 236 in Immunology and Microbiology, placing it within the top 94th and 93rd percentiles respectively. Since its inception in 1987, TRENDS IN IMMUNOLOGY has provided a critical platform for researchers, professionals, and students to access the latest advancements and integrative reviews in immunological research. The journal offers open access options, enhancing the accessibility of its high-impact content to a global audience. Researchers and practitioners rely on its pages not only for cutting-edge findings but also for comprehensive discussions that drive the future of immunology research.

Cell Reports Medicine

Exploring the nexus of biochemistry and clinical practice.
Publisher: CELL PRESSISSN: 2666-3791Frequency: 12 issues/year

Cell Reports Medicine, published by Cell Press, represents a pivotal advancement in the open access landscape of biomedical research since its inception in 2020. With a dedicated focus on the intersection of medicine, biochemistry, genetics, and molecular biology, this journal has quickly established itself as a key resource, earning a remarkable Q1 ranking in these fields. Based in the United States, Cell Reports Medicine boasts impressive metrics, ranking #25 out of 636 in General Medicine and #18 out of 221 in Biochemistry, underscoring its influence and reach within the scientific community, with a notable 96th and 92nd percentile respectively. As a fully open access journal, it fosters global dissemination of knowledge, ensuring that groundbreaking research is readily available to researchers, professionals, and students alike. The journal not only promotes high-quality research but also aims to bridge the gap between molecular discoveries and clinical applications, making it an essential addition to any academic library or researcher's toolkit.

Biomarker Insights

Empowering researchers with cutting-edge biomarker knowledge.
Publisher: SAGE PUBLICATIONS LTDISSN: 1177-2719Frequency: 1 issue/year

Biomarker Insights, published by SAGE Publications Ltd, is a leading open-access journal dedicated to advancing the field of biomarker research and its applications in health and disease. With an ISSN of 1177-2719 and an E-ISSN of 1177-2719, this journal has been at the forefront of disseminating high-quality scientific findings since its inception in 2006. Based in New Zealand, it has achieved a notable impact within the academic community, ranking in Q2 for Biochemistry (medical) and Molecular Medicine, and Q1 in Pharmacology as of 2023. This positions Biomarker Insights as a critical resource for researchers, professionals, and students alike, looking to explore innovative methodologies and applications in biomarker discovery and validation. With a commitment to open access, the journal ensures that groundbreaking research is readily available to the global community, fostering collaboration and innovation in the ever-evolving field of biomedical sciences.

Med

Elevating Healthcare Through Innovative Discoveries.
Publisher: CELL PRESSISSN: 2666-6340Frequency: 12 issues/year

Med, an esteemed journal published by CELL PRESS, stands at the forefront of interdisciplinary medical research, making significant contributions to the field of Medicine since its inception in 2020. With an impressive Q1 ranking in the Medicine (miscellaneous) category and a notable 96th percentile ranking in General Medicine according to Scopus, this journal is dedicated to disseminating high-quality research that advances medical knowledge and practice. Med provides a platform where researchers, professionals, and students can share their findings and insights, fostering a collaborative environment that bridges various aspects of medicine. While offering a comprehensive body of research, Med is committed to promoting open communication within the scientific community, ensuring that valuable information is accessible to those who seek to enhance their understanding and application of medical science. With a strong presence in the United States and a global readership, Med is poised to influence the future of healthcare significantly.